# Fresenius Kabi opens €15M biosimilar R&D center in Eysins, Switzerland

Fresenius Kabi SwissBioSim opened a new R&D center for biosimilars in Eysins, Switzerland, with an investment of about €15 million. The center will focus on autoimmune diseases and oncology, and currently employs over 100 people.

- Type: Expansion
- Announced: 2019-09-18
- Where: Eysins, Switzerland, Switzerland
- Value: $16.5M (15.0M EUR)
- Jobs: 100
- Starts operating: 18 Sep 2019
- Status: completed
- Products: biosimilars
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Fresenius Kabi](https://endata.com/companies/9091.md)

## Sources

- [bioalps.org](https://bioalps.org/fresenius-kabi-expands-biosimilar-research-activities-in-eysins/), 2019-09-18: "Fresenius Kabi SwissBioSim, a Fresenius Kabi company, opened a new research and development center for biosimilars in Eysins, Switzerland."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.